Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2538

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 6
Chunk 2538
---
 reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement
will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2024.

Item 14. Principal Accountant Fees and Services.

The information required
under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement
will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2024.

112

PART IV

Item 15. Exhibit and Financial Statement Schedules.

(1)For a list of the financial statements included herein, see Index to the Consolidated Financial Statements
on page F-1 of this Annual Report, incorporated into this Item by reference.

(2)Financial statement schedules have been omitted because they are either not required or not applicable
or the information is included in the consolidated financial statements or the notes thereto.

(3)Exhibits:

The following list of exhibits
includes exhibits submitted with this Annual Report as filed with the SEC and those incorporated by reference to other filings.

    Exhibit No.
     
    Description

    2.1
     
    Business Combination Agreement, dated as of June 4, 2023, by and among
    Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc., as amended (incorporated by reference to Exhibit
    2.1 to the Current Report on Form 8-K filed by Phoenix Biotech Acquisition Corp. with the Securities and Exchange Commission on June
    5, 2023).

    2.2
     
    Amendment No. 1 to the Business Combination Agreement, dated as of
    February 5, 2024, by and among Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc. (incorporated
    by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Phoenix Biotech Acquisition Corp. with the Securities and
    Exchange Commission on February 6, 2024).

    2.3
     
    Amendment No. 2 to the Business Combination Agreement, dated as of
    February 13, 2024, by and among Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc